Elevated Risk of Rare Blood Cancers After Chemotherapy for Most Solid Tumors Identified

by Colleen Fleiss on December 23, 2018 at 11:37 PM

Elevated Risk of Rare Blood Cancers After Chemotherapy for Most Solid Tumors Identified
Patients treated with chemotherapy for most solid tumors during 2000-2014 were found to experience a higher risk of therapy-related myelodysplastic syndrome/acute myeloid leukemia (tMDS/AML), stated findings from a new study conducted by researchers at the National Cancer Institute (NCI).

The study, which used U.S. population-based cancer registry data from NCI's Surveillance, Epidemiology, and End Results (SEER) program and treatment information from the SEER-Medicare database, was published in JAMA Oncology. NCI is part of the National Institutes of Health. Advances in treatment over the last several decades have resulted in improved survival for patients with many types of cancer. However, survivors may be at increased risk of developing a subsequent treatment-related cancer.

"We've known for a long time that the development of myeloid leukemia is a very rare adverse effect of some types of cancer treatments that damage cells," said Lindsay Morton, Ph.D., lead author of the study and a senior investigator in NCI's Division of Cancer Epidemiology and Genetics. "There have been many changes in cancer treatment over time, including the introduction of new chemotherapy drugs and drug combinations, but we didn't know what the risk of therapy-related leukemia looked like for patients since these changes were made."

Because tMDS/AML is rare, most data on the disease have come from case series, case-control studies, and clinical trials, which often include a relatively small number of tMDS/AML cases. In this study, investigators brought a population-based data approach to the research, with a much larger sample size and prospective data from long-term patient follow-up.

To this end, they analyzed SEER registry data on more than 700,000 patients age 20-84 in the United States with solid tumors who were diagnosed and treated with initial chemotherapy during 2000-2013 and survived at least one year after diagnosis. Of these patients, 1,619 developed tMDS/AML through 2014. When the researchers analyzed the risk of tMDS/AML by original cancer type, they found that risk was increased by 1.5-fold to more than 10-fold for 22 of the 23 solid cancer types investigated (all except colon cancer).

These findings expand the groups of survivors at risk of tMDS/AML following treatment with chemotherapy because, in the past, excess risks were established only after chemotherapy for cancers of the lung, ovary, breast, soft tissue, testis, and brain/central nervous system. In the present analysis, cumulative incidence of tMDS/AML was less than 1 percent at 10 years after chemotherapy for most solid cancer types. However, prognosis following tMDS/AML diagnosis was very poor.

Because information on the specific chemotherapy agents was not available in the SEER registry data, the researchers used the SEER-Medicare linked database to examine the patterns of use of specific chemotherapy agents during the same time period. Among 165,000 patients in the SEER-Medicare database who received initial chemotherapy for a first primary solid cancer during the study period, 2000-2013, there was a substantial rise in use of platinum-based chemotherapy agents, from 57 percent of patients in 2000-2001, to 81 percent of patients in 2012-2013. Platinum-based chemotherapy agents are known to increase risk of tMDS/AML.

"The most important message from this study is that, while advances in cancer treatment approaches have improved the prognosis for many types of cancer, the number of patients at risk of developing rare, therapy-related leukemia after cancer chemotherapy in the modern treatment era has markedly expanded," Dr. Morton said. "Assessments of treatment risks and benefits should balance these risks and other adverse effects of chemotherapy against potential gains in survival following treatment for the initial solid cancer."

Source: Eurekalert

News A-Z
News Category
What's New on Medindia
'Hybrid Immunity' may Help Elude COVID-19 Pandemic
Stroop Effect
Plant-Based Diet may Reduce the Risk of COVID-19
View all

Medindia Newsletters Subscribe to our Free Newsletters!
Terms & Conditions and Privacy Policy.

More News on:
Thalassemia Chronic Lymphocytic Leukemia Hodgkins Lymphoma Non-Hodgkins Lymphoma Chemotherapy Chemotherapy Drugs Peritoneal Cancer Rhabdomyosarcoma Male Breast Cancer Blood in Stools - Symptom Evaluation 

Recommended Reading
Chronic Lymphocytic Leukemia
Chronic Lymphocytic Leukemia (CLL) is one of the most common types of adult leukemia and is ......
Quiz on Leukemia
Making up for 2.9% of all cancers, Leukemia is a serious condition. Do you know all about it? ......
Chemotherapy Drugs
Chemotherapy drugs perform like 'magic bullets' to destroy cancer cells in the body....
Best Treatment for Mixed Phenotype Acute Leukemia Identified
Patients initially treated with acute lymphoblastic leukemia (ALL) therapy are more likely to ......
Blood in Stools - Symptom Evaluation
Blood in stools results from bleeding that arises from any part of the digestive tract. Causes of bl...
‘Chemo’ means medicine or ‘drug’; ‘therapy’ means ‘treatment’. Chemotherapy refers to the use of cy...
Hodgkins Lymphoma
Hodgkins lymphoma or Hodgkins disease has the distinction of being the first cancer to be cured by c...
Male Breast Cancer
Most cases of male breast cancer are diagnosed between the ages of 60 and 70 years. Treatment of mal...
Non-Hodgkins Lymphoma
Non Hodgkins Lymphoma is a cancer that affects the lymph tissues. It is made up of a wide array of ....
Peritoneal Cancer
Peritoneal cancer is a rare cancer that develops in the peritoneum. Peritoneal cancers may be primar...
Rhabdomyosarcoma is a rare type of cancer affecting the striated muscles. It mostly occurs in ......
Thalassemia is an inherited blood disorder passed on through parental genes causing the body to prod...

Disclaimer - All information and content on this site are for information and educational purposes only. The information should not be used for either diagnosis or treatment or both for any health related problem or disease. Always seek the advice of a qualified physician for medical diagnosis and treatment. Full Disclaimer

© All Rights Reserved 1997 - 2021

This site uses cookies to deliver our services. By using our site, you acknowledge that you have read and understand our Cookie Policy, Privacy Policy, and our Terms of Use